Why should elderly AML patients take part in clinical trials?
Using PET to determine treatment response in Hodgkin lymphoma
Understanding the complexity of acute myeloid leukemia (AML)
Smouldering myeloma: detection, risk stratification and defining a new standard of care
Safety and efficacy of venetoclax plus LDAC in treatment-naive AML patients aged ≥ 65 years